The first massive pharma takeover of 2016 is already approaching
Baxalta, which is based in Deerfield, Illinois, was spun off from healthcare company Baxter in July 2015. Baxalta's focus is primarily on developing biotechnology treatments for blood disorders, cancer, and immune deficiency disorders.
It didn't take long after Baxalta went public for Shire to reach out and try to acquire the company. Shire originally made an unsolicited offer of $30 billion in stock. That offer was rejected by Baxalta.
The two sides returned to talks last month, and now Bloomberg reports that the deal could go through as soon as this week, citing people familiar with the matter.
The drug industry has been gripped by a takeover wave as large pharma companies tap low-cost debt to fund purchases of smaller rivals. Only two deals in the last twelve months - Pfizer's $183 billion purchase of Allergan and Allergan's $40 billion sale of its generic-drugs business, are larger than the reported value of the Baxalta deal.
Shire is a Dublin-based pharmaceutical company makes drugs to treat everything from ADHD to dry eye disease, and is focused on developing drugs for rare diseases. Bloomberg reports the company expects to launch 30 new drugs over the next five years.
If Baxalta accepts the deal, the acquisition would give the company a lower tax rate because it too would move its headquarters to Ireland, a move that has lately drawn a fair amount of criticism .
More from this author
- Business Insider is hiring a science reporter
- 14 science-backed ways to sleep better
- 15 places where computer science majors dream of w...
- Ad tech company Audience Science is shutting down
- How to take the perfect vacation, according to sci...
- Science says happier people have these 9 things in...
- 9 science-backed ways to appear more attractive